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The dopamine transporter (DAT) plays a key role in the regulation
of dopaminergic signaling wherein it controls both the spatial and
temporal actions of dopamine. Here we evaluated the behavioral
and neurochemical consequences of increased DAT function by
generating DAT transgenic mice (DAT-tg) that overexpress the
transporter. These mice were generated by pronuclear injection of
a bacterial artificial chromosome containing the mouse DAT locus,
yielding an anatomical expression pattern of DAT-tg identical to
WT. In DAT-tg mice there is a 3-fold increase in the levels of total
and membrane-expressed DAT, but synaptic plasma membrane
fractions of DAT-tg mice show only a 30% increase in transporter
levels. Functional studies reveal that in the DAT-tg animals there is
a 50% increase in the rate of dopamine (DA) uptake resulting in
extracellular levels of DA that are decreased by 40%. Behavior-
ally, DAT-tg animals display similar locomotor stimulation when
treated with DAT blockers such as GBR12909, methylphenidate,
and cocaine. However, these mice demonstrate markedly increased
locomotor responses to amphetamine compared with WT animals.
Furthermore, compared with controls, there is a 3-fold greater
increase in the amount of DA released by amphetamine in DAT-tg
mice that correlates with the 3-fold increase in protein expression.
Finally, DAT-tg animals show reduced operant responding for
natural reward while displaying preference for amphetamine at
much lower doses (0.2 and 0.5 mg/kg) than WT mice (2 mg/kg).
These results suggest that overexpression of DAT leads to a
marked increase in sensitivity to psychomotor and rewarding
properties of amphetamine.
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Dopamine (DA) is a key neurotransmitter regulating motivatedbehaviors such as food intake, locomotion, and reward, and its
dysregulation is associated with a number of psychiatric and neu-
rological disorders including schizophrenia, Parkinson’s disease,
drug addiction, attention deficit hyperactivity disorder (ADHD),
and depression (1–3). A key step in the control of DA neurotrans-
mission is the reuptake of DA into presynaptic neurons by the
dopamine transporter (DAT) (4). DAT, as well as the serotonin
transporter (SERT) and norepinephrine transporter (NET), be-
longs to the large family of Na/Cl-dependent transporters that
also includes the transporters for glycine and GABA (5, 6). These
transporters comprise 12 transmembrane domains and intracellular
N- and C-terminal domains. Once at the plasma membrane, DAT
cotransports two Na, one Cl, and one DA molecule from the
extracellular space into the cytosolic compartment of the neuron.
Much insight regarding how DAT affects DA homeostasis has
been gained from the study of mice lacking the DAT (DAT
knockout; DAT-KO) (4, 7). In these animals, there is a 5-fold
increase in the extracellular concentration of DA (8). The crucial
role of DAT in determining the duration of action of extracel-
lular DA has also been demonstrated in these animals. Using
cyclic voltametry, it was shown that there is a 300-fold increase
in the lifetime of extracellular DA in DAT-KO animals com-
pared with their WT littermates (7, 8). In addition to the changes
observed in the extracellular dynamics of DA, profound alter-
ations in both the pre- and postsynaptic neurons of DAT-KO
animals have also been documented. In the nigrostratial dopa-
minergic projections there is a 95% decrease in the content of
DA despite a 1.5- to 2-fold increase in DA synthesis (8).
Behaviorally, the absence of DAT translates in a marked in-
crease in locomotor activity in a novel environment, disturbances
in the prepulse inhibition of startle reflex (PPI), and multiple
behavioral abnormalities related to cognitive inflexibility (4). In
addition to its role as a key regulator of DA homeostasis in the
brain, DAT is also a major target of psychostimulants such as
amphetamine. It is believed that amphetamine can enter DA
neurons through DAT and/or passive transmembrane diffusion.
Once inside the terminal, amphetamine acts at DA containing
vesicles and dissipates the proton gradient, resulting in the
redistribution of DA from its vesicular localization to the
cytoplasm (9). Ultimately, the increased cytoplasmic concentra-
tion of DA and the direct action of amphetamine on DAT lead
to the reversal of the transporter and DA efflux from the
intracellular to the extracellular space (9). The elevated DA in
the dorsal and ventral striatum is thought to be a critical
determinant of the psychomotor, rewarding, and addictive prop-
erties of amphetamine. Amphetamine also has a long history of
therapeutic application in ADHD patients for the treatment of
symptoms such as hyperactivity, impulsivity, and inattention
(10). It has been postulated that, at therapeutic doses used in
patients, amphetamine treatment results in enhanced DA trans-
mission, leading to the hypothesis that there is a hypofunction of
the DA system in ADHD (11). This hypothesis has been further
encouraged by the observation that there is a 70% increase in the
levels of DAT in ADHD subjects (12), but this still remains
controversial (13).
To directly assess the role of increased DAT levels in the
physiological functions and responses to amphetamine, we gen-
erated DAT transgenic (DAT-tg) animals by pronuclear injec-
tion of a bacterial artificial chromosome (BAC) containing the
mouse DAT locus and 80 kb of upstream and downstream
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genomic sequence. We report here that DAT-tg animals have a
3-fold increase in the expression levels of DAT with a conse-
quent 40% reduction in the concentration of extracellular DA in
the striatum. These animals display increased behavioral re-
sponses to the stimulant and rewarding effects of amphetamine,
indicating that DAT levels are critical for these properties of
amphetamine. Furthermore, these data suggest that hypofunc-
tion of the DA system through increased DAT expression does
not recapitulate important endophenotypes related to ADHD,
such as hyperactivity and the seemingly paradoxical inhibitory
responses to amphetamine.
Results
Generation of Transgenic Animals Overexpressing DAT. Because the
promoter region of the DAT is not well characterized (14), a
BAC transgenic approach was used for the overexpression of
DAT. The BAC chosen for the generation of the transgene in
this study contains the murine DAT locus (40 kb) and 80 kb of
up and downstream genomic sequence surrounding the DAT
locus (Fig. 1A). A BAC transgenic founder line was generated by
pronuclear injection and characterized for the extent of DAT
overexpression achieved. First, the number of transgene copies
integrated in the genome of the mice was estimated by Southern
blot analysis using a probe specific for DAT. As shown in Fig. 1B,
there is an increase in the intensity of the genomic fragment from
DAT-tg on the Southern blot. Densitometric analysis shows that
there is a 3-fold increase in the levels of genomic DAT in the
transgenic line compared with the WT, indicating that there are
four copies of transgene integrated in the genome, bringing the
total number of DAT copies to six in the DAT-tg animals. The
observation of simple Mendelian inheritance of the transgene
indicates that the four transgene copies have integrated in
tandem presumably at a single locus. In accordance with the
increased genomic copies of DAT, there is a 3-fold increase in
the levels of DAT protein in the transgenic animals compared
with WT controls as measured by Western blot of striatal
preparations (Fig. 1C).
Next, the expression pattern of DAT within the transgenic line
was examined by immunohistochemistry. As shown in Fig. 2, in
both WT and DAT-tg animals DAT antibodies label dopami-
nergic neurons that originate in substantia nigra and ventral
tegmental area with major projections to the striatum. In the
DAT-tg animals the DA axon tracts are more apparent than in
the WT animals (Fig. 2 A and B). Fig. 2 C and D shows coronal
sections at the level of the DA cell bodies from WT and DAT-tg
demonstrating the fidelity of the transgene expression. The
proper expression of DAT in the DAT-tg mice was further
demonstrated by detailed immunhistochemical analysis of coro-
nal sections through the telencephalon, diencephalon, and mes-
encephalon of these mice as well as double labeling with tyrosine
hydroxylase antibody [supporting information (SI) Figs. 7 and 8].
The subcellular localization of DAT was characterized by using
electron microscopy and is shown in Fig. 3. In agreement with
prior ultrastructural descriptions in the rat (15–17), immunore-
activity for DAT in both WT and DAT-tg mice is localized
exclusively to small-caliber axons and axon varicosities that
occasionally form short symmetric synapses on distal dendrites
and spines (Fig. 3). Most of the gold–silver particles for DAT are
associated with the plasma membrane; however, DAT is also
present within intracellular compartments in both WT and
DAT-tg animals (Fig. 3C, small arrows). In striatal sections from
DAT-tg mice, the density of gold–silver labeling per axonal
profile is increased, both on the plasma membrane and in the
cytoplasm. Consequently, the overall proportion of gold–silver
particles that are distributed to the plasmalemma is roughly the
same in DAT-tg (82.5  22.9%, mean  SD; n  499 profiles in
four mice) and WT mice (81.0  22.4%; n  1,332 profiles in
four mice). According to a generalized linear mixed model (see
SI Text), the odds ratio of gold particles representing DAT being
observed on the plasma membrane for DAT-tg versus WT mice
was 0.98 with 95% confidence intervals of 0.70–1.36. These
results are consistent with a nearly symmetrical distribution (i.e.,
no preferred direction) of 1.0, indicating no detectable differ-
ence between groups. A secondary two-sample t test confirmed
the lack of detectable difference between groups (t6  0.30,
P  0.775), again with a nearly symmetrical distribution of
confidence intervals (0.102–0.080). Where immunoreactive
axons form synapses, DAT labeling appears to be distributed
mainly to the edges of the junction in a perisynaptic location
(white arrow in Fig. 3C), consistent with prior observations in the
rat striatum (16). To further investigate the subcellular localiza-
Fig. 1. Generation of DAT-tg animals. (A) Schematic representation of the
BAC clone used for the generation of the DAT-tg animals. (B) Representative
DAT Southern blot analysis from WT and DAT-tg animals. Data are means 
SEM (four per group). (C) Representative DAT Western blot analysis of striatal
tissue from WT and DAT-tg animals. Data are means  SEM (five per group).
***, P  0.001.
Fig. 2. Immunohistochemical localization of DAT. Saggital sections (A and B)
and coronal sections (C and D) of WT and DAT-tg show the expression pattern
of DAT by immunoperoxidase labeling. cp, cerebral peduncle; IP, intrapedun-
cular nucleus; ml, medial lemniscus.
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tion of DAT, membrane fractionation experiments were carried
out on striatal tissues from WT and DAT-tg animals. As shown
in Fig. 3D, there is a 2.5-fold increase in the levels of DAT in the
total membrane fraction from DAT-tg animals compared with
their WT littermates; however, when synaptic plasma membrane
(SPM) fractions are isolated from the total fraction, the increase
in the levels of DAT observed in the DAT-tg samples is only
1.3-fold of the WT. This observation suggests that perhaps some
specific cellular components required for the proper SPM tar-
geting of DAT may be limiting in the DAT-tg animals.
DAT Function in DAT-tg Animals. As a first step to assess the amount
of functional DAT in the DAT-tg mice we assessed its levels by
3[H]WIN 35428 radioligand binding. Fig. 4A shows that there is
a 38% increase in the measurable levels of DAT in DAT-tg mice
(2,190  170 fmol/mg) compared with the WT (1,490  30
fmol/mg) in agreement with the increases observed in the SPM
samples. We next evaluated the clearance of DA in these
animals. In DAT-KO animals DA clearance is essentially re-
duced to the rate of diffusion (8); thus, it would be expected that,
in DAT-tg animals expressing increased levels of DAT, DA
clearance should be faster and kinetics of DA uptake should be
increased. To evaluate these parameters, fast scan cyclic volta-
metry (FSCV) on striatal slices of WT and DAT-tg animals was
performed. As shown in Fig. 4B, the initial clearance of evoked
DA (Vmax) is substantially faster in slice preparations from
DAT-tg animals than in those from WT animals, confirming that
there is a functional increase in the levels of DAT in the DAT-tg
animals. Interestingly, the determined KM values for DA uptake
are very similar in both WT (0.37  0.09 M) and DAT-tg
(0.47  0.07 M) animals, indicating that the affinity of DAT for
DA is unchanged in the DAT-tg animals (Fig. 4C). However,
using a Michaelis–Menten-based kinetic analysis, we found that
there is a 60% increase in the uptake rate for DA in DAT-tg
Fig. 3. Subcellular localization of DAT by electron microscopy and mem-
brane fractionation. Dorsal striatum of WT (A and B) and DAT-tg (C) mice show
the density of Immunogold–silver labeling for DAT. Immunoreactive axons are
identified by asterisks, with two profiles cut longitudinally indicated by mul-
tiple asterisks (B and C). Small black arrows indicate cytoplasmic gold particles;
all other gold particles are associated with the plasma membrane. The large
white arrow shows a synapse formed by the longitudinally sectioned axon
most likely onto the neck of a spine. Immunoreactivity for DAT occurs in a
perisynaptic location. (Scale bar: 500 nm.) (D) Representative DAT Western
blot analysis of total or synaptic plasma membrane fractions from WT and
DAT-tg animals. Data are means  SEM (six per group in duplicates). *, P 
0.05; ***, P  0.001.
Fig. 4. Analysis of DAT function. (A) Levels of DAT determined by 3[H]WIN
35428 radioligand binding. (B) Release and clearance of DA measured by FSCV
in striatal slices from WT and DAT-tg animals after a single-pulse stimulation.
The color plot topographically depicts the voltammetric data, with time on x
axis, applied scan potential on the y axis, and background-subtracted current
measured on the z axis in pseudocolor (27). The white dashed line denotes the
location of the stimulation. (Bottom) Dopamine concentrations obtained
every 16 ms over a 2-s interval where traces monitor the release (ascending
curve) and reuptake (descending curve) of DA. (C) Km values of WT and DAT-tg
animals for DA determined by FSCV. Data are means  SEM (n  4 per group).
(D) Uptake rates (Vmax) of DAT for DA in WT and DAT-tg animals measured by
FSCV. Data are means  SEM (n  4 per group). (E) Extracellular levels of DA
in the striatum of freely moving WT (n  4) and DAT-tg (n  7) mice as
determined by quantitative low-perfusion-rate microdialysis. Data are
means  SEM. *, P  0.05; ***, P  0.001.








animals (7.48  0.10 M/s) compared with WT animals (4.63 
0.18 M/s), consistent with the notion of increased transporter
activity and levels in DAT-tg animals (Fig. 4D). Furthermore,
using a quantitative ‘‘low-perfusion-rate’’ microdialysis on freely
moving animals we observed that there is there is a 40%
reduction in the extracellular concentration of DA in the DAT-tg
animals (6.2  1.1 nM) compared with WT controls (10.7  1.1
nM) (Fig. 4E). Together these observations indicate that the
overexpressed transporter in DAT-tg animals is functional and
that its activity leads to increased clearance and reduced extra-
cellular levels of DA and thus to hypodopaminergia.
Increased Locomotor Response to Amphetamine in DAT-tg Mice. To
evaluate how reduced levels of DA in DAT-tg animals would
affect their locomotion, basal and psychostimulant-induced lo-
comotor activity of WT and DAT-tg animals was examined. As
shown in Fig. 5A, there is no significant difference in the basal
locomotion of WT and DAT-tg animals for total distance
traveled during 60 min. Likewise, the DAT inhibitors
GBR12909, methylphenidate, and cocaine induce similar loco-
motor activities in WT and DAT-tg animals (Fig. 5B). However,
upon injection with amphetamine (0.5, 1, 2, and 3 mg/kg), there
is a remarkable increase in locomotor activity (shown as total
distance) in DAT-tg animals compared with their WT litter-
mates (Fig. 5C). This increase in locomotor activity is presum-
ably due to a marked increase in extracellular levels of DA after
amphetamine treatment of DAT-tg animals compared with WT
mice as measured by conventional microdialysis experiments
performed on freely moving animals (Fig. 5 D and E). Interest-
ingly, the increase in DA release in the DAT-tg animals after
amphetamine is approximately three times higher than that of
their WT littermates (Fig. 5E), in agreement with the increased
levels of total DAT protein in the Tg animals (Fig. 1C).
Importantly, although DAT-tg animals do not display any dis-
cernable basal locomotor phenotype compared with their WT
littermates, crossing the DAT-tg to DAT-KO animals com-
pletely abolishes the novelty-induced hyperactivity observed in
DAT-KO animals (Fig. 5F), indicating that the transgenic ex-
pression of DAT in the DAT-tg animals can fully replace and
rescue the function of the endogenous DAT allele inactivated in
DAT-KO animals. Furthermore, it should be noted that in-
creased responses to amphetamine were also observed in an-
other line of transgenic mice overexpressing an HA-tagged
DAT. These mice were generated by using the same BAC
construct described above in addition to harboring an HA
epitope (data not shown). These results indicate that the effects
described here are unlikely to result from a founder/insertion
effect.
Increased Rewarding Properties of Amphetamine but Not Natural
Reward in DAT-tg Mice. Next we evaluated whether the DAT-tg
animals also showed an increased sensitivity to the rewarding
effects of amphetamine. For this, conditioned place preference
(CPP) experiments were carried out testing the rewarding effects
of amphetamine in WT and DAT-tg animals. As shown in Fig.
6A, DAT-tg animals display CPP at lower doses of amphetamine
(0.2 and 0.5 mg/kg) compared with the WT animals. In fact, at
amphetamine concentrations of 2 mg/kg, where there is a modest
CPP in WT animals, DAT-tg animals no longer display place
preference. The shift of the CPP response to lower doses of
amphetamine suggests that DAT-tg animals are more sensitive
to the rewarding effects of amphetamine.
Because DAT-tg mice display enhanced sensitivity to the
rewarding effects of amphetamine, we also examined their
responsiveness to natural reward. For this, an operant behavioral
Fig. 5. Locomotor analysis. (A) Basal locomotion of WT and DAT-tg animals
as measured by total distance over a 60-min period. Data are means  SEM
(n  8 per group). (B) Total distance traveled during 60 min after i.p. injection
of GBR12909 (10 mg/kg), methylphenidate (20 mg/kg), and cocaine (20 mg/kg)
to WT and DAT-tg animals that were habituated for 60 min. Data are means 
SEM (n  8 per group). (C) Total distance traveled during 60 min after i.p.
injection of amphetamine to WT and DAT-tg animals that were habituated for
60 min. Data are means  SEM (n  8 per group). (D) Extracellular striatal DA
dynamics in WT and DAT-tg mice as determined by conventional microdialysis
after i.p. injection of amphetamine (3 mg/kg) to animals. Data are presented
as percentage of average level of DA measured in at least three samples
collected before the drug administration. Data are means  SEM (n  5–8 per
group). (E) Calculation of the fold increase in DA release after amphetamine
injection in WT and DAT-tg animals. Data are means  SEM (n  5–8 per
group). (F) Basal locomotor activity of WT, DAT-KO, and crosses between
DAT-KO and DAT-tg animals (DAT-KO/tg) as measured by total distance over
a 60-min period in the open field. Data are means  SEM (n  5–8 per group).
*, P  0.05; ***, P  0.001.
Fig. 6. Responsiveness of DAT-tg animals to psychostimulant and natural
rewards. (A) Amphetamine-induced CPP in WT and DAT-tg animals. CPP was
performed as described in Materials and Methods. Data are shown as the
difference in the time spent in the amphetamine-associated chamber vs. the
saline-associated chamber on the test day and the preconditioning day. Data
are means  SEM (n  7–12 animals). *, P  0.05; #, P  0.062. (B) Results of
operant responding of WT and DAT-tg animals for sweet liquid reward. The
experiments were conducted as described in Materials and Methods. Shown
are the number of lever presses during the first 15 min for WT and DAT-tg
animals (six per group) for different dilutions of sweetened condensed milk.
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paradigm was designed to measure the propensity of WT and
DAT-tg animals to lever-press for different dilutions of sweet-
ened condensed milk. As shown in Fig. 6B, WT animals show a
bell-shaped dose–response curve of lever presses for the dilu-
tions of sweetened condensed milk, with maximal lever pressing
seen at the 1/2 dilution milk concentration. Although DAT-tg
animals show a similar bell-shaped curve, they lever-press sig-
nificantly less than the WT animals for two of the concentrations
tested, indicating that DAT-tg animals exhibit reduced operant
responding for this natural reward compared with WT animals.
This observation is consistent with the notion that DA is a
central determinant involved in natural reward and that animals
with reduced levels of extracellular DA would be expected to
show a reduced response for the tested natural food reward.
Furthermore, the increased amphetamine-mediated reward ob-
served in the CPP experiments occurs despite reduced respon-
siveness of DAT-tg animals to natural reward.
Discussion
In this study we describe a genetically modified mouse line in which
four additional copies of the DAT gene have been incorporated.
These mice show a 3-fold increase in DAT protein expression with
an 50% increase in DAT functional activity. This increase in DAT
activity leads to a 40% reduction of extracellular DA; however, no
change in the basal locomotor phenotype of the transgenic mice is
observed. A striking observation made with the DAT-tg mouse is
their increased responsiveness to the locomotor and rewarding
effects of amphetamine.
The mouse line described in this study was generated by BAC
transgenic technology, using a clone of the complete DAT locus
(40 kb) flanked by 80 kb of upstream and downstream genomic
sequence. Our results indicate that the essential elements re-
quired for the proper spatial expression of DAT are located
within this sequence and specify expression in dopaminergic
neurons, reaffirming prior observations that BAC transgenesis
recapitulates the native expression pattern of the gene of interest
(18). This was of particular importance because previously
reported transgenic animals expressing DAT under the control
of the tyrosine hydroxylase promoter region had only a modest
overexpression of DAT in several brain regions that is not
restricted to dopaminergic neurons (19).
The fraction of total membrane expressed DAT in the DAT-tg
animals mirrors that observed in WT animals, where the ma-
jority of the protein is localized at the plasmalemma membrane
with some transporters detected in intracellular compartments.
Despite the fact that there is a 3-fold increase in both the DAT
protein and amphetamine-induced DA efflux in DAT-tg ani-
mals, there is only a 30% increase in the levels of DAT in the
SPM fraction of DAT-tg animals, which leads to a 38% increase
in 3[H]WIN 35428 binding. Consequently, there is a 60% in-
crease in DA uptake in striatal tissues that is accompanied by a
40% reduction of extracellular brain DA concentration in these
animals compared with WT. These observations are quite
intriguing because the global membrane localization of the DAT
in DAT-tg animals seems to be very similar to what is observed
in WT, whereas its subcellular SPM localization is not increased
to the same level. These results suggest that the fraction of DAT
involved in DA uptake and 3[H]WIN 35428 binding is the one
localized to the SPM, whereas all membrane localized DAT can
be substrate for amphetamine-induced DA efflux. This in turn
suggests that other regulatory mechanisms, besides transporter
levels, have to be considered for uptake and binding activity.
Indeed, it has been reported that interaction of DAT with several
cytosolic proteins can influence both its membrane localization
and its uptake activity (20). It is possible that levels of these
proteins expressed in dopaminergic neurons could become
limiting and allow only an 30–50% increase in DAT uptake
activity despite a 300% increase in protein expression. Alterna-
tively, the perisynaptic compartment where DAT proteins are
localized could itself be limiting in allowing increases of DAT
incorporation, which may explain the relatively minor (30%)
increases observed in synaptic fractions. Further studies will be
required to elucidate what other mechanisms, beyond trans-
porter levels, could limit the transporter activity in the DAT-tg
animals.
Although many studies have evaluated the effect of DA
receptor antagonists in reward-related behaviors (21), our work
is based on a genetic manipulation resulting in reduced levels of
extracellular DA due to DAT overexpression. Our results indi-
cate that the DAT-tg animals have a reduced propensity to
lever-press for food reward. This does not seem to be due to a
reduced ability of these animals to sense the food, because, like
WT animals, they also show an inverted U-shaped curve for the
dilutions of milk. It thus appears that the DAT-tg animals have
a modest reduction in motivation to work for the specific natural
reward tested here.
In contrast to this operant behavior, the DAT-tg animals show
a remarkable increase in amphetamine-induced locomotor ac-
tivation and an increased sensitivity to the rewarding effects of
amphetamine. This increased responsiveness to amphetamine is
in accord with the molecular mechanism of amphetamine action
in which its DA-releasing activities are dependent on DAT (9).
Indeed, we and others (22–24) have reported that the DAT
heterozygous animals, or animals in which DAT expression has
been reduced by 50% via siRNA treatment, demonstrate a
commensurate reduction in amphetamine-induced locomotor
activation. It thus seems clear that the locomotor-stimulating
effects of amphetamine are absolutely dependent and directly
proportional to the levels of DAT. In contrast, the locomotor
stimulant effects of DAT blockers such as GBR12909, methyl-
phenidate, and cocaine are similar in WT and DAT-tg animals.
This indicates that elevations in DA levels resulting from inhi-
bition of reuptake after neuronal activity-dependent vesicular
DA release are substantially less susceptible to DAT overex-
pression than amphetamine-dependent changes in DA levels. It
is also important to note that the basal locomotor activity of the
DAT-tg animals is not different from that of the WTs, whereas
DAT-KO or DAT knockdown (DAT-KD) animals show a
significant increase in novelty-induced hyperlocomotion (7, 25).
Furthermore, in DAT-KO or DAT-KD animals (hyperdopam-
inergic), amphetamine treatment results in a marked reduction
of their locomotor behavior, whereas amphetamine treatment of
DAT-tg animals results in a dramatic increase in the locomotor
activity.
In conclusion, we show that mice with selective overexpression
of DAT in DA neurons have a 40% functional reduction in
extracellular brain DA concentration with no discernible effects
on their basal locomotor phenotype. However, these animals
display a marked increase in amphetamine-induced locomotion
and reward. These observations indicate that the sensitivity of
animals to the stimulant and rewarding effects of amphetamine
seem to be directly proportional to the levels of DAT. At the
same time, our results indicate that this mouse model of DAT
overexpression does not recapitulate the hyperactivity endophe-
notype and responses to amphetamine seen in ADHD that have
been linked to increased DAT expression (12). In fact, the
observations presented in this study, as well as previous reports
on DAT-KO and DAT-KD animals (22, 25), are more in line
with a recent study that actually found modest decreases in DAT
levels in drug-naı̈ve adult ADHD patients rather than an over-
expression of DAT (13), suggesting that symptoms of ADHD
might be more consistent with loss rather than gain of DAT
function in humans.









Animals. For all experiments we used age- and gender-matched WT and
DAT-tg mice (3–5 months old) maintained on a C57BL/6J genetic background.
All behavioral experiments were performed during the light cycle. Experi-
ments were conducted in accordance with the National Institutes of Health
guidelines for the care and use of animals and an approved animal protocol
from the Duke University Animal Care and Use Committee.
Generation of DAT-tg Mice. A BAC containing the mouse DAT locus was obtained
from Genome Sciences. The BAC4 clone was chosen for pronuclear injection
because the DAT locus (40 kb) is flanked by 80 kb of downstream and upstream
genomic sequences. The BAC DNA was isolated by using the Clontech BAC
preparation kit. The isolated BAC DNA was resuspended at 2 ng/l in injection
buffer (0.03 mM spermine/0.07 mM spermidine). Pronuclear injections were
carried out by the Duke Transgenic Mouse Facility using C57BL/6J embryos. One
transgene positive founder was identified by PCR-based genotyping using oligos
that recognize BAC vector sequences (forward, 5-gcatcagccagcgcagaaatatttcc;
reverse, 5-gatacttcgttatcgacaccagctgc-3). This founder was further bred for
characterization of the transgene outlined in this study.
Southern Blot. Genomic DNA was isolated from tail biopsy after Proteinase K
digestionandisopropanolprecipitation.Atotalof8gofgenomicDNAwasused
for overnight EcoRI digestion. Nitrocellulose membranes were hybridized in
QuikHyb buffer (Stratagene) with a radiolabeled probe generated by PCR am-
plification of primers 5-tggagctcatcttggtcaag-3 and 5-tacaccatgccctgcacaca-3,
which correspond to sequences within and 3 of DAT exon 1, respectively.
Western Blot. Brain samples were mechanically homogenized in RIPA buffer
(50 mmol/liter TrisHCl, pH 7.4/150 mmol/liter NaCl/1% Nonidet P-40/0.5%
sodium deoxycholate/0.1% SDS; Sigma) plus protease inhibitor mixture
(Roche 1873580). Protein concentration was measured by using a DC protein
assay (Bio-Rad). Protein extracts (30 g) were separated by 10% SDS/PAGE and
transferred to nitrocellulose membranes. Blots were immunostained over-
night at 4°C with anti-DAT (1:1,000 dilution; Chemicon MAB369) as a primary
antibody and revealed with peroxidase-conjugated secondary antibodies
(Jackson ImmunoResearch) and a chemiluminescent reagent (SuperSignal
West-Pico; Pierce). Densitometric analysis was carried out by scanning the film
with a Fluor-S multiimager (Bio-Rad) and quantifying the bands using Quan-
tity One software (Bio-Rad).
Microdialysis. In vivo microdialysis measurements of striatal extracellular DA
levels in freely moving mice were performed at least 24 h after implantation
of a microdialysis probe as described previously (26). Dialysate samples were
assayed for DA by using HPLC-EC. On day 1 of the experiment (24 h after
operation), a quantitative low-perfusion-rate microdialysis approach with
perfusion flow rate of 70 nl/min was applied to reliably establish basal extra-
cellular levels of DA. On day 2 of the experiment (48 h after operation), a
conventional microdialysis experiment (perfusion flow rate 1 l/min) was
performed to assess the effect of amphetamine on extracellular DA levels.
Locomotor Analysis. Locomotor activity was assessed in automated locomotor
activity monitors (Accuscan Instruments). Mice were initially placed into the
activity monitor chamber (20 cm  20 cm) for 60 min, then injected with
vehicle (10 ml/kg of body weight i.p.) or the drug, returned to the chamber,
and monitored for 60 min after injection. Locomotor activity was measured in
terms of the total distance covered unless indicated otherwise.
Statistics. Data are reported as means  SEM. Statistical significance was
evaluated by two-tailed t test or one- or two-way ANOVA, as appropriate.
Additional Details. See SI Text for a description of 3[H]WIN 35428 binding,
histology, FSCV, and CPP.
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